- Home
- IMCR vs SGML Comparison
IMCR vs SGML Comparison
Compare IMCR & SGML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCR | SGML |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IMCR | SGML |
|---|---|---|
| Price | $31.45 | $9.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $66.33 | $18.75 |
| AVG Volume (30 Days) | 329.7K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.39 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $14.57 | $272.11 |
| Revenue Next Year | $8.21 | $36.70 |
| P/E Ratio | $136.91 | ★ N/A |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.56 | $4.62 |
| 52 Week High | $40.71 | $24.48 |
Technical Indicators
Market Signals| Indicator | IMCR | SGML |
|---|---|---|
| Relative Strength Index (RSI) | 30.70 | 33.60 |
| Support Level | $30.47 | N/A |
| Resistance Level | $33.55 | $13.22 |
| Average True Range (ATR) | 1.11 | 0.61 |
| MACD | -0.68 | -0.39 |
| Stochastic Oscillator | 9.06 | 4.67 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds full interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil. Geographically, the company operates in Switzerland; United Arab Emirates; Singapore; and Republic of Korea, of which it derives maximum revenue from Switzerland.